國家衛生研究院 NHRI:Item 3990099045/16289
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12189/12972 (94%)
造訪人次 : 979327      線上人數 : 819
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/16289


    題名: 2024 guidelines of the Taiwan society of cardiology on the primary prevention of atherosclerotic cardiovascular disease --- Part II
    作者: Chao, TH;Lin, TH;Cheng, CI;Wu, YW;Ueng, KC;Wu, YJ;Lin, WW;Leu, HB;Cheng, HM;Huang, CC;Wu, CC;Lin, CF;Chang, WT;Pan, WH;Chen, PR;Ting, KH;Su, CH;Chu, CS;Chien, KL;Yen, HW;Wang, YC;Su, TC;Liu, PY;Chang, HY;Chen, PW;Juang, JJ;Lu, YW;Lin, PL;Wang, CP;Ko, YS;Chiang, CE;Hou, CJ;Wang, TD;Lin, YH;Huang, PH;Chen, WJ
    貢獻者: Institute of Cellular and Systems Medicine;Institute of Population Health Sciences
    摘要: For the primary prevention of atherosclerotic cardiovascular disease (ASCVD), the recommended treatment target for each modifiable risk factor is as follows: reducing body weight by 5-10%; blood pressure < 130/80 mmHg (systolic pressure < 120 mmHg in high-risk individuals); low-density lipoprotein cholesterol (LDL-C) < 100 mg/dL in high-risk individuals, LDL-C < 115 mg/dL in moderate-risk individuals, LDL-C < 130 mg/dL in low-risk individuals, and LDL-C < 160 mg/dL in those with a minimal; complete and persistent abstinence from cigarette smoking; hemoglobin A1C < 7.0%; fulfilling recommended amounts of the six food groups according to the Taiwan food guide; and moderate-intensity physical activity 150 min/wk or vigorous physical activity 75 min/wk. For the primary prevention of ASCVD by pharmacological treatment in individuals with modifiable risk factors/clinical conditions, statins are the first-line therapy for reducing LDL-C levels; some specific anti-diabetic drugs proven to be effective in randomized controlled trials for the primary prevention of ASCVD are recommended in patients with type 2 diabetes mellitus; pharmacological treatment is recommended to assist in weight management for obese patients with a body mass index ≥ 30 kg/m(2) (or 27 kg/m(2) who also have at least one ASCVD risk factor or obesity-related comorbidity); an angiotensin-converting enzyme inhibitor, a glucagon-like peptide-1 receptor agonist, a sodium-dependent glucose cotransporter-2 inhibitor, and finerenone can be used in diabetic patients with chronic kidney disease for the primary prevention of ASCVD. Of note, healthcare providers are at full discretion in clinical practice, owing to the diversity of individuals and practice, and the availability of resources and facilities.
    日期: 2024-11
    關聯: Acta Cardiologica Sinica. 2024 Nov;40(6):669-715.
    Link to: http://dx.doi.org/10.6515/acs.202411_40(6).20240724b
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1011-6842&DestApp=IC2JCR
    顯示於類別:[吳志成] 期刊論文
    [潘文涵] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    PUB39582845.pdf1200KbAdobe PDF6檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋